Editorial
Hidden messages in optical coherence tomography: looking beyond fluid
Abstract
The outlook for patients with neovascular age-related macular degeneration (AMD) has significantly improved since the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy. Numerous clinical trials have demonstrated favorable visual and anatomical response up to 2 years. However, longer-term results have been variable.
